CN109414403A - 口服胃滞留制剂及其用途 - Google Patents
口服胃滞留制剂及其用途 Download PDFInfo
- Publication number
- CN109414403A CN109414403A CN201780041708.3A CN201780041708A CN109414403A CN 109414403 A CN109414403 A CN 109414403A CN 201780041708 A CN201780041708 A CN 201780041708A CN 109414403 A CN109414403 A CN 109414403A
- Authority
- CN
- China
- Prior art keywords
- dosage unit
- polymer
- delivery device
- pharmaceutical dosage
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360744P | 2016-07-11 | 2016-07-11 | |
| US62/360,744 | 2016-07-11 | ||
| PCT/IL2017/050783 WO2018011798A1 (en) | 2016-07-11 | 2017-07-11 | Oral gastroretentive formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109414403A true CN109414403A (zh) | 2019-03-01 |
Family
ID=59388117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780041708.3A Pending CN109414403A (zh) | 2016-07-11 | 2017-07-11 | 口服胃滞留制剂及其用途 |
Country Status (17)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796142A (zh) * | 2022-04-08 | 2022-07-29 | 黄山学院 | 萘普生胃漂浮片及其制备方法 |
| CN117224522A (zh) * | 2023-11-15 | 2023-12-15 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018152334A1 (en) * | 2017-02-15 | 2018-08-23 | Molecular Infusions, Llc | Formulations |
| BR102018002843A2 (pt) * | 2018-02-09 | 2019-08-27 | Prati, Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
| WO2020037410A1 (en) * | 2018-08-20 | 2020-02-27 | Hexo Operations Inc. | Cannabis-infused product with enhanced cannabinoid profile user experience |
| GB2584341B (en) * | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CN114650809A (zh) | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP2022551730A (ja) | 2019-10-14 | 2022-12-13 | パイク セラピューティクス,インコーポレイテッド | カンナビジオールの経皮送達 |
| US20210177740A1 (en) * | 2019-12-11 | 2021-06-17 | Joel Studin | Transpore delivery of cannabinoid and uses thereof |
| EP4084790A1 (en) * | 2020-01-02 | 2022-11-09 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Floating drug delivery systems comprising cannabinoids |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023272335A1 (en) * | 2021-06-30 | 2023-01-05 | Emyria | Cannabidiol formulation comprising a matrix pellet forming excipient |
| TW202430130A (zh) * | 2022-10-18 | 2024-08-01 | 大陸商南京三迭紀醫藥科技有限公司 | 用於胃滯留的口服藥物劑型 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110092583A1 (en) * | 2005-11-07 | 2011-04-21 | Murty Pharmaceuticals, Inc. | Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery |
| CN102149369A (zh) * | 2008-04-18 | 2011-08-10 | 因泰克制药有限公司 | 卡比多巴/左旋多巴胃滞留给药 |
| WO2012059815A1 (en) * | 2010-11-01 | 2012-05-10 | Intec Pharma Ltd. | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03163011A (ja) * | 1989-08-31 | 1991-07-15 | Yamanouchi Pharmaceut Co Ltd | 胃内滞留デバイス |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
| PT1903866E (pt) | 2005-11-07 | 2016-06-09 | Murty Pharmaceuticals Inc | Distribuição melhorada de tetra-hidrocanabinol |
| DK2997953T3 (en) | 2006-01-18 | 2019-04-15 | Intec Pharma Ltd | ADMINISTRATION ORAL ADMINISTRATION |
| WO2010064139A2 (en) * | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Zaleplon gastroretentive drug delivery system |
| WO2011048494A2 (en) | 2009-10-19 | 2011-04-28 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
| US8808734B2 (en) | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
| KR20160002709A (ko) * | 2013-02-12 | 2016-01-08 | 코버스 파마수티컬스, 아이엔씨. | 초고순도 테트라하이드로카나비놀-11-오익산 |
| WO2015025312A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
-
2017
- 2017-07-11 RU RU2019103297A patent/RU2019103297A/ru not_active Application Discontinuation
- 2017-07-11 NZ NZ750422A patent/NZ750422A/en unknown
- 2017-07-11 AU AU2017296351A patent/AU2017296351A1/en not_active Abandoned
- 2017-07-11 KR KR1020197002888A patent/KR20190026799A/ko not_active Ceased
- 2017-07-11 CN CN201780041708.3A patent/CN109414403A/zh active Pending
- 2017-07-11 JP JP2018568785A patent/JP2019527208A/ja active Pending
- 2017-07-11 WO PCT/IL2017/050783 patent/WO2018011798A1/en not_active Ceased
- 2017-07-11 CA CA3027700A patent/CA3027700A1/en not_active Abandoned
- 2017-07-11 MX MX2019000348A patent/MX2019000348A/es unknown
- 2017-07-11 SG SG10202100182TA patent/SG10202100182TA/en unknown
- 2017-07-11 EP EP17743090.7A patent/EP3481371A1/en not_active Withdrawn
- 2017-07-11 US US16/316,390 patent/US20190224118A1/en not_active Abandoned
- 2017-07-11 BR BR112018077541-0A patent/BR112018077541A2/pt not_active Application Discontinuation
- 2017-07-11 SG SG11201811209QA patent/SG11201811209QA/en unknown
-
2019
- 2019-01-02 IL IL264065A patent/IL264065A/en unknown
- 2019-01-09 PH PH12019500061A patent/PH12019500061A1/en unknown
- 2019-01-15 ZA ZA2019/00275A patent/ZA201900275B/en unknown
- 2019-01-23 CO CONC2019/0000643A patent/CO2019000643A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110092583A1 (en) * | 2005-11-07 | 2011-04-21 | Murty Pharmaceuticals, Inc. | Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery |
| CN102149369A (zh) * | 2008-04-18 | 2011-08-10 | 因泰克制药有限公司 | 卡比多巴/左旋多巴胃滞留给药 |
| WO2012059815A1 (en) * | 2010-11-01 | 2012-05-10 | Intec Pharma Ltd. | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
Non-Patent Citations (1)
| Title |
|---|
| JIE OONG ET AL: ""Current Pharmaceutical Treatments and Alternative Therapies of Parkinson"s Oisease"", 《CURRENT NEUROPHARMACOLOGY》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796142A (zh) * | 2022-04-08 | 2022-07-29 | 黄山学院 | 萘普生胃漂浮片及其制备方法 |
| CN117224522A (zh) * | 2023-11-15 | 2023-12-15 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019527208A (ja) | 2019-09-26 |
| CA3027700A1 (en) | 2018-01-18 |
| ZA201900275B (en) | 2020-05-27 |
| NZ750422A (en) | 2021-10-29 |
| BR112018077541A2 (pt) | 2019-04-30 |
| SG11201811209QA (en) | 2019-01-30 |
| WO2018011798A1 (en) | 2018-01-18 |
| PH12019500061A1 (en) | 2019-10-14 |
| MX2019000348A (es) | 2019-03-28 |
| RU2019103297A3 (cg-RX-API-DMAC7.html) | 2020-11-06 |
| SG10202100182TA (en) | 2021-02-25 |
| AU2017296351A1 (en) | 2019-02-28 |
| EP3481371A1 (en) | 2019-05-15 |
| KR20190026799A (ko) | 2019-03-13 |
| CO2019000643A2 (es) | 2019-04-30 |
| RU2019103297A (ru) | 2020-08-11 |
| IL264065A (en) | 2019-01-31 |
| US20190224118A1 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190224118A1 (en) | Oral gastroretentive formulations and uses thereof | |
| KR101411100B1 (ko) | 친지성 약물을 함유하는 나노캡슐을 포함하는 미소구체 | |
| CA2438097C (en) | Cannabinoids pharmaceutical formulations | |
| Musthaba et al. | Status of novel drug delivery technology for phytotherapeutics | |
| AU2006311818B2 (en) | Improved delivery of tetrahydrocannabinol | |
| DK2432455T3 (en) | A composition comprising oil droplets | |
| US20160184258A1 (en) | Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts | |
| JP2019527208A5 (cg-RX-API-DMAC7.html) | ||
| WO2016022936A1 (en) | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts | |
| WO2012033478A1 (en) | An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery | |
| CN1228020A (zh) | 多层渗透装置 | |
| Zeng et al. | Optimization of the process variables of tilianin-loaded composite phospholipid liposomes based on response surface-central composite design and pharmacokinetic study | |
| US20050037073A1 (en) | Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof | |
| US20150342893A1 (en) | Celecoxib formulations useful for treating colorectal cancer | |
| AU2016203127A1 (en) | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts | |
| Gottemukkula et al. | SNEDDS as lipid-based nanocarrier systems: Concepts and formulation insights | |
| WO2024142045A1 (en) | Controlled-release oral formulations of lipophilic drugs | |
| HK1261258A1 (zh) | 口服胃滞留制剂及其用途 | |
| CA2533400A1 (en) | Cannabinoids pharmaceutical formulations | |
| Naser | Depot-forming Microarray Patches for the Long-acting Delivery of Atorvastatin | |
| Salooria et al. | Solid Lipid Nanoparticles based Hydrogel of Mycophenolate Mofetil for the treatment of Psoriasis | |
| Rani | Nanoparticles Based Transdermal Patches for the Treatment of Schizophrenia | |
| WO2015176780A1 (en) | Celecoxib formulations useful for treating colorectal cancer | |
| CN118103032A (zh) | 包括氘代丁苯那嗪的多微粒剂型 | |
| HK1159475B (en) | Scf extract containing cardiac glycoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1261258 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190301 |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1261258 Country of ref document: HK |